Biocon Ltd’s Board on Saturday accredited elevating as much as Rs 4,500 crore by way of Certified Institutional Placement in a number of tranches and a Rs 6,950 crore preferential share situation to amass stakes in Biocon Biologics Ltd., from current buyers, as a part of its plan to create a unified world biopharmaceutical chief.
The preferential situation will contain 17.12 crore fairness shares of Biocon at a worth decided underneath SEBI norms, aggregating as much as Rs 6,950 crore, for consideration aside from money by way of a swap of BBL securities.
Shares will likely be allotted to promoting shareholders together with Mylan Inc., Serum Institute Life Sciences, Tata Capital Progress Fund II, and Activ Pine LLP, topic to shareholder and regulatory approvals.
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our e-newsletter, and be a part of our rising neighborhood at nextbusiness24.com
